Floatz logo

Lucitanib

MBC

Clovis Oncology, Inc.Small moleculePhase 2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the MBC cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Lucitanib is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →